



US00D963164S

(12) **United States Design Patent** (10) **Patent No.:** **US D963,164 S**  
**Marsala** (45) **Date of Patent:** **\*\* Sep. 6, 2022**

(54) **SURGICAL NEEDLE**  
(71) Applicant: **The Regents of the University of California, Oakland, CA (US)**

5,871,487 A 2/1999 Warner et al.  
5,891,164 A \* 4/1999 Dabir ..... A61B 17/06066  
606/222  
6,159,233 A \* 12/2000 Matsuzawa ..... A61B 17/06066  
606/223

(72) Inventor: **Martin Marsala, Solana Beach, CA (US)**

(Continued)

(73) Assignee: **The Regents of the University of California, Oakland, CA (US)**

**FOREIGN PATENT DOCUMENTS**

CN 101528922 A 9/2009  
CN 103328038 A 9/2013

(Continued)

(\*\*) Term: **15 Years**

**OTHER PUBLICATIONS**

(21) Appl. No.: **29/720,014**

Bu et al. "Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single gene," Proc. Natl. Acad. Sci. USA, Mar. 1992, 89:2115-2119.

(22) Filed: **Jan. 9, 2020**

(Continued)

(51) **LOC (13) Cl.** ..... **24-02**

(52) **U.S. Cl.**  
USPC ..... **D24/145**

(58) **Field of Classification Search**  
USPC ..... D24/145, 112-114, 108, 130, 127, 133, D24/186; 606/181, 185; 604/264, 604/523-528, 272, 164.01-164.11, 187, 604/93.01; 600/101, 139, 143; 128/200.24, 207.14, 207.15  
CPC .. A61M 25/065; A61M 5/42; A61M 25/0612; A61M 25/00; A61B 17/06066  
See application file for complete search history.

*Primary Examiner* — David G Muller  
(74) *Attorney, Agent, or Firm* — Foley & Lardner LLP

(57) **CLAIM**

The ornamental design for a surgical needle, as shown and described.

**DESCRIPTION**


FIG. 1 is a rear, left, and bottom perspective view of a surgical needle;  
FIG. 2 is a front elevational view thereof;  
FIG. 3 is a rear elevational view thereof;  
FIG. 4 is a right side elevational view thereof;  
FIG. 5 is a left side elevational view thereof;  
FIG. 6 is a top plan view thereof;  
FIG. 7 is a bottom plan view thereof; and,  
FIG. 8 is a rear, left, bottom perspective view of the surgical needle shown disposed within a holder.  
The broken lines in the figures represent portions of the article or environment that form no part of the claimed design.

(56) **References Cited**

**U.S. PATENT DOCUMENTS**

3,394,704 A \* 7/1968 Dery ..... A61B 17/06004  
606/224  
4,128,351 A \* 12/1978 Kurtz ..... A61B 17/06066  
30/168  
5,041,127 A \* 8/1991 Troutman ..... A61B 17/06066  
606/223  
5,433,728 A \* 7/1995 Kim ..... A61B 17/06066  
606/205  
5,478,327 A \* 12/1995 McGregor ..... A61B 17/06066  
604/239

**1 Claim, 4 Drawing Sheets**





(56)

## References Cited

## U.S. PATENT DOCUMENTS

6,530,943	B1 *	3/2003	Hoepffner .....	A61B 17/06004 606/222
8,214,996	B2 *	7/2012	Stametz .....	A61B 17/06004 29/515
8,292,874	B2	10/2012	Stivland et al.	
D691,267	S *	10/2013	Marsteller .....	D24/150
9,259,219	B2 *	2/2016	Maurer .....	C09D 183/04
9,445,837	B2 *	9/2016	Fulton, III .....	A61B 8/481
9,827,109	B2	11/2017	Steinberg	
D837,982	S *	1/2019	Adler .....	D24/145
10,548,628	B2 *	2/2020	Swaney .....	A61B 17/3417
10,688,285	B2	6/2020	Marsala et al.	
D937,417	S *	11/2021	Cichocki, Jr. ....	D24/145
D938,031	S *	12/2021	Sivaraman .....	D24/147
2002/0042607	A1	4/2002	Palmer et al.	
2002/0082390	A1	6/2002	Friddle et al.	
2002/0095124	A1	7/2002	Palasis et al.	
2003/0069398	A1	4/2003	Rippmann et al.	
2003/0130577	A1	7/2003	Purdy et al.	
2003/0195633	A1	10/2003	Hyde, Jr.	
2005/0085790	A1	4/2005	Guest et al.	
2006/0205999	A1	9/2006	Berger et al.	
2007/0142748	A1	6/2007	Deshmukh et al.	
2008/0051357	A1	2/2008	Chang et al.	
2008/0154262	A1	6/2008	Brundobler et al.	
2010/0004625	A1	1/2010	Boulis	
2010/0023021	A1	1/2010	Flaherty	
2010/0030184	A1	2/2010	Boulis et al.	
2010/0198189	A1	8/2010	Marsala	
2012/0221063	A1	8/2012	Abdou	
2013/0211380	A1	8/2013	Aquino et al.	
2014/0058357	A1	2/2014	Keyser et al.	
2014/0073684	A1	3/2014	Stoffel et al.	
2014/0256801	A1	9/2014	Glorioso et al.	
2015/0224331	A1	8/2015	Marsala	
2015/0343038	A1	12/2015	Marsala	
2016/0081956	A1	3/2016	Kaufman et al.	
2018/0008727	A1	1/2018	Marsala	
2018/0117282	A1	5/2018	Marsala et al.	
2019/0071486	A1	3/2019	Marsala	

## FOREIGN PATENT DOCUMENTS

WO	1994/10988	A	5/1994
WO	2004/060464	A2	7/2004
WO	WO-2006/047554		5/2006
WO	2008/112177	A2	9/2008
WO	2010/071832	A1	6/2010
WO	2011/057171	A1	5/2011
WO	2012/075337	A2	6/2012
WO	2014/047540	A1	3/2014
WO	2014/116652	A2	7/2014
WO	2014/184576	A2	11/2014
WO	2016/122791	A1	8/2016
WO	WO-2017/172606		10/2017

## OTHER PUBLICATIONS

Chaudhry et al. "The Vesicular GABA Transporter, VGAT, Localizes to Synaptic Vesicles in Sets of Glycinergic as Well as GABAergic Neurons," *The Journal of Neuroscience*, Dec. 1, 1998, 18(23):9733-9750.

PCT/US2020/013059 International Search Report and Written Opinion dated Apr. 1, 2020.

Poston et al. "Catheter delivery systems for infusions into the cortex," *Journal of Medical Engineering & Technology*, Jul. 2011, 35(5):246-253.

Kantor et al. "Clinical Applications Involving CNS Gene Transfer," *Adv Genet.*, 2014, 87:71-124.

Bouard et al. "Viral vectors: from virology to transgene expression," *British Journal of Pharmacology*, 2009, 157:153-165.

Adkins et al. "Tiagabine: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in the Management of Epilepsy," *Drugs*, Mar. 1998, 55(3):437-460.

Gholizadeh et al. "Transduction of the Central Nervous System After Intracerebroventricular Injection of Adeno-Associated Viral Vectors in Neonatal and Juvenile Mice," *Human Gene Therapy Methods*, Aug. 2013, 24:205-213.

EP14742941 Extended European Search Report dated Jun. 20, 2016.

Dayton et al. "The advent of AAV9 expands applications for brain and spinal cord gene delivery," *Expert Opinion on Biological Therapy*, Jun. 15, 2012, 12(6):757-766.

Federici et al. "Robust spinal motor neuron transduction following intrathecal delivery of AAV9 in pigs," *Gene Therapy*, 2012, 19(8):852-859.

Foust et al. "Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes," *Nature Biotechnology*, Jan. 2009, 27(1):59-65.

Hirai et al. "Intrathecal shRNA-AAV9 Inhibits Target Protein Expression in the Spinal Cord and Dorsal Root Ganglia of Adult Mice," *Human Gene Therapy Methods*, Apr. 1, 2012, 23(2):119-127.

Kakinohana et al. "Combinational Spinal GAD65 Gene Delivery and Systemic GABA-Mimetic Treatment for Modulation of Spasticity," *PloS One*, Jan. 2012, 7(1):e30561.

PCT/US2017/024285 International Search Report and Written Opinion dated Aug. 10, 2017.

Jin et al. "Demonstration of Functional Coupling between Gamma-Aminobutyric acid (GABA) Synthesis and Vesicular GABA Transport into Synaptic Vesicles," *Proc Natl Acad Sci USA*, Apr. 2003, 100(7):4293-4298.

EP15880645 Extended European Search Report dated May 24, 2018.

Colak et al. "Adenovirus-mediated gene therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome," *Brain Research*, May 1995, 691:76-82.

JP2017-540569 Office Action dated Jun. 26, 2018.

PCT/US2015/065704 International Search Report dated Feb. 25, 2016.

CN201580078566.9 Office Action dated Sep. 24, 2019.

JP2017-540569 Office Action dated Jun. 4, 2019.

Bell et al. "Motor Neuron Transduction After Intracisternal Delivery of AAV9 in a *Cynomolgus* Macaque," *Human Gene Therapy Methods*, Apr. 2015, 26:43-44.

Duque et al. "Intravenous Administration of Self-complementary AAV9 Enables Transgene Delivery to Adult Motor Neurons," *Molecular Therapy*, Jul. 2009, 17(7):1187-1196.

Foust et al. "Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS," *Molecular Therapy*, Dec. 2013, 21(12):2148-2159.

Gray et al. "Preclinical Differences of Intravascular AAV9 Delivery to Neurons and Glia: A Comparative Study of Adult Mice and Nonhuman Primates," *Molecular Therapy*, Jun. 2011, 19(6):1058-1069.

Kakinohana et al. "Region-specific cell grafting into cervical and lumbar spinal cord in rat: a qualitative and quantitative stereological study," *Experimental Neurology*, 2004, 190:122-132.

Meyer et al. "Improving Single Injection CSF Delivery of AAV9-mediated Gene Therapy for SMA: A Dose-response Study in Mice and Nonhuman Primates," *Molecular Therapy*, Mar. 2015, 23(3):477-487.

Passini et al. "Translational Fidelity of Intrathecal Delivery of Self-Complementary AAV9-Survival Motor Neuron 1 for Spinal Muscular Atrophy," *Human Gene Therapy*, Jul. 2014, 25:619-630.

Usvald et al. "Analysis of Dosing Regimen and Reproducibility of Intraspinal Grafting of Human Spinal Stem Cells in Immunosuppressed Minipigs," *Cell Transplantation*, 2010, 19:1103-1122.

Xiao et al. "Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus," *Journal of Virology*, Mar. 1998, 72(3):2224-2232.

Xu et al. In Vivo Gene Knockdown in Rat Dorsal Root Ganglia Mediated by Self-Complementary Adeno-Associated Virus Serotype 5 Following Intrathecal Delivery, *PLoS One*, Mar. 2012, 7(3):e32581.

CN201580078566.9 Office Action dated Apr. 28, 2020.

(56)

**References Cited**

OTHER PUBLICATIONS

PCT/US2018/049914 International Search Report and Written Opinion dated Nov. 21, 2018.

"*H.sapiens* mRNA for glutamate decarboxylase, GenBank: X69936.1," GenBank, Mar. 16, 1993 [Retrieved from the Internet: <https://www.ncbi.nlm.nih.gov/nucleotide/X69936>].

EP17776384.4 Extended European Search Report dated Jul. 31, 2019.

Kitzman, Patrick. "Changes in vesicular glutamate transporter 2, vesicular GABA transporter and vesicular acetylcholine transporter labeling of sacrocaudal motoneurons in the spastic rat," *Experimental Neurology*, 2006, 197:407-419.

\* cited by examiner




FIG. 1



FIG. 2




FIG. 3






FIG. 4

FIG. 5



FIG. 6




FIG. 7




FIG. 8